Imagine being middle aged and starting to feel that you are off balance a lot and that you are having a hard time coordinating your movements. Those are among the symptoms of Spinocerebellar ataxia type 6, known as SCA6, a rare neurodegenerative disease which typically appears in adulthood and worsens over time. Over time, other problems such as slurred speech and difficulty seeing or seeing double, may also appear. It is estimated that fewer than 5,000 people in the US have the condition, which is the result of genetic mutations in the cerebellum.
The disease currently has no cure. But this may change, thanks to a new discovery made by McGill researchers.
In a recent article in Acta Neuropathologica, researchers from McGill University, led by Professor Alanna Watt of the Department of Biology, describe a discovery, that suggests possible paths towards new treatments.
They have been able to show that damaged mitochondria in the cells of the cerebellum, the part of the brain that plays a role in movement and balance but also in cognitive functions such as language and attention, most likely contribute to the progression of the disease.
“Mitochondria are commonly known as cell powerhouses because they generate the energy the cell needs to function,” said Sophia Leung, a PhD student in the Watt lab and the paper's first author. “When we looked at a mouse model of SCA6, we observed that the mitochondria were failing to generate that crucial power. What’s more, we found that the power outages were worsening as the disease worsened.”
The researchers also found that observations of human post-mortem tissue corroborated what they had found in mice, which suggests that this finding is relevant for the human disease.
“It’s an exciting finding because it suggests a promising new treatment target for patients living with this disease,” adds Alanna Watt, the senior author on the paper.
The study:
“Mitochondrial damage and impaired mitophagy contribute to disease progression in SCA6” by Leung, T.C.S., Fields, E., Rana, N. et al. was published in Acta Neuropathologica.
DOI: 10.1007/s00401-023-02680-z
About McGill University
Founded in Montreal, Quebec, in 1821, McGill University is Canada’s top ranked medical doctoral university. McGill is consistently ranked as one of the top universities, both nationally and internationally. It is a world-renowned institution of higher learning with research activities spanning three campuses, 12 faculties, 14 professional schools, 300 programs of study and over 39,000 students, including more than 10,400 graduate students. McGill attracts students from over 150 countries around the world, its 12,000 international students making up 30% of the student body. Over half of McGill students claim a first language other than English, including approximately 20% of our students who say French is their mother tongue.
